Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.2089 -0.0013 (-0.62%)
Streaming Delayed Price Updated: 11:01 AM EDT, Sep 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Status Update on Clinical Development Programs
Via Investor Brand Network
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO Highlights 2022 as ‘Momentous Year’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Study Finds Using Social Media May Negatively Affect Youths’ Mental Health
Via Investor Brand Network
Cybin Highlights 2022 Accomplishments and Milestones
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Presents CYB003 Preclinical Data Amongst Leading Scientists, Academics in Neuropsychopharmacology
Via Investor Brand Network
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Recent Business Highlights, Presentation of CYB003 Preclinical Data at Neuroscience 2022
Via Investor Brand Network
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022
From Cybin Inc.
Via Business Wire
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Retirement
Exposures Pension Product Safety
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Progress on Clinical Path for CYB004
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation Schedule for Upcoming Investor Events
Via Investor Brand Network
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit
Via Investor Brand Network
Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Graduates Class of Facilitators
Via Investor Brand Network
Cybin’s EMBARK Program Announces Graduation of Facilitators
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Continues Focus to Create the Best Psychedelic Therapies for Patients
Via Investor Brand Network
TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), The Chopra Foundation Note World Mental Health Day
Via Investor Brand Network
Psychedelic Drugs Prove Their Worth In Clinical Trials
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial... 
Via PressReach
Cybin & The Chopra Foundation Recognize World Mental Health Day
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) ‘Focused on Adding Targeted IP’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Provides Update on its Intellectual Property Portfolio
From Cybin Inc.
Via Business Wire
Colorado to Vote on Legalizing Psychoactives in November
Voters in Colorado will have a say in the legalization of psychedelic drugs this November as an initiative to legalize psilocybin mushrooms and other naturally occurring psychedelics appears on the... 
Via PressReach
Topics Supply Chain
Exposures Supply Chain
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
From Cybin Inc.
Via Business Wire
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminalized psychedelics, a meeting was held by the City... 
Via PressReach
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 22, 2022 – Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one... 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.